Eventually, you run out of other people's money:
The bulk of Gov. Deval Patrick’s emergency budget cuts hit providers of care to Medicaid recipients, with over half of the spending reductions being taken from rates paid to MassHealth providers.
What's the beef? Everyone has insurance!
The Sacramento Bee: Avoid Pitfalls of ObamaCare by Learning to Stay Healthy with Pamela Young's "Natural Healing Foods"
Avoid the thresher!
The two following headlines popped up near each other in the ol' NewsReader tonight…
#1. "Massachusetts enjoys nation's broadest health-insurance coverage".
I've been seeing headlines like that since late 2006 after Massachusetts (and Biff Romney) passed a law MAKING IT ILLEGAL NOT TO HAVE INSURANCE. Since then, countless twits like G. Scott Thomas, above, have marvelled, with no sense of irony, that citizens comply with the coercion they are powerless to resist, with not a care or mention of that coercion.
#2. "Mass. insurance costs again listed as most expensive in the nation".
Gosh. It's almost as if an artificially distorted market is trying to rebalance itself in the only way available to it, or something, with the coercive actors forced by their own mandates to keep the distortive pressure on.
Ain't it a wonder?
I was reading this story about the coming socialist suffocation of heath care when it occurred to me that what is unfolding for health care is what has already transpired for our socialist education system.
What happens vis a vis education is that middle class property owners and income earners are heavily taxed to pay for the public, government-run schools and are thereby locked into said system. While rich people can afford to pay the taxes that go toward the government schools and still can afford the pop for superior private schools, the middle class just doesn't have the luxury, and can only exercise a limited amount of choice via secondary stratagems such as buying houses in relatively superior school districts, with much of their education dollars still siphoned off to pay for the educations of those with no money to contribute to the system. The government schools, themselves, forced to cater to a broad "customer" base that includes a significant proportion who either have no interest in being educated, or suffer from ancillary issues like hunger or mental illness, and with many of its officials and practitioners more interested in the perks that unionism provides rather than a competent instruction of reading, writing, and arithmetic, can hardly be expected to deliver a product approaching sufficient. The vast majority of Americans are locked into a mediocre system.
And so it will go with health care. In order to pay for the health care of millions of people who can't or won't pay for it themselves, the middle class will be locked into a health care system that is barely capable of catering to a lowest common denominator, and the new system will confiscate enough of the taxpayer's health care dollars, and a little more, that none but the richest will be able to afford non-government-approved services.
I wonder if people will begin shopping for houses near to hospitals that are more generous or competent in the care dispensed.
"I smile, of course"*
Practice manager Lynne McCormick said about 700 of the surgery's 2,500 patients need the vaccine.
She said: "I'm worried if we don't get enough, we will be left to decide who gets them.
"We don't want to be in that situation and we don't want to play God with people's health in that way.
"I have one for a young chap who is having chemotherapy. But other than that, we have nothing."
Is it really playing God if it's just government policy? I thought not.
*Good ol' TS…
The October night comes down; returning as before
Except for a slight sensation of being ill at ease
I mount the stairs and turn the handle of the door
And feel as if I had mounted on my hands and knees.
Around here we call it Rocktober, but we feel it, man.
After reading this, I have to say that I'm with future President Mittens, and that the country should start rationing "End of Life Care" for NPR listeners. And don't forget Garrison Keillor.
She used to earn $365,000 a year:
"Two years ago, we made history together by finally passing health reform," said Mrs. Obama. "And because we passed this law, insurance companies will now have to cover basic preventive care–things like prenatal care, mammograms, contraception–at no extra cost."
… but you have to wonder what for.
How does one acquire "things like prenatal care, mammograms, contraception–at no extra cost"?
How does one delude oneself into believing that such things are acquired like manna from heaven?
More importantly, how does one go about spouting that nonsense without being laughed unto obscurity, or run out of town, or tarred and feathered and then dumped on the outskirts of town?
Is it such a laughable question?
There was its brother at Ezra Klein's place: Should Warren Buffett’s cancer get treated? (written by one of Klein's blogging minions)
One of my comments:
Even the phrasing of the question is odious.
Since "cancer" has no volition, it can't "get" anything, with the additional observation that the use of the word "get" in the manner above is always suspect.
Also, the awkward phrasing seems to be an attempt to dehumanize the issue, to make it as though the man, Warren Buffet, is an afterthought in the equation. Why not ask, "Should Warren Buffet treat his cancer?" Or does that put the human element too much to the fore?
And most importantly, as others have pointed out, it's nobody's business but Buffet's. Of course, the propagandists at Klein's like to keep these sorts of questions in the public mind, inuring people to the idea of making such decisions as a collective.
All in all, another Wonkbook disgrace.
Stupid Ezra Klein reported without comment the words of Obama, today (yesterday), which included…
[I]n the absence of an individual mandate, you cannot have a mechanism to ensure that people with preexisting conditions can actually get health care.
To which I belatedly offered:
Oh, I don't know. How about, say, a medium of exchange. For lack of a better word, let's call it "money". If you need health care, you pay "money". If you don't have any "money", you make arrangements to acquire some, or solicit others to provide some on your behalf. If you don't have enough "money" at the present time, hospitals and doctors are known to accept periodic payments in lieu of a lump sum.
Or, there is President Obama's preferred way. Have the Congress put on their hoodies and mug your neighbors for the "money".
It's the Democratic way.
Some of the less reported goodies in the goodness, by Hsieh.
Why should fat people take precedence over the elderly in the NHS?
Good question! We should be throwing fat people into the cannibal pot.
Nick Budnick pretends to write a meaningful story about people pretending to be concerned about the problem of drug shortages.
There isn't a single iota of anything in the piece, or at any of the links Budnick showcases, having anything to do with the real causes of the problem or (ipso facto) any remedy that even pretends to address said problem.
Hint to Budnick: Quotas, price controls, a thousand paper cuts of arbitrary regulations, and a hostile political climate will turn excess capacity into insufficient capacity in any business.
Dr. Kate Scannell, plainly out of her league, laments:
It's stunning that we would need to invent a law to discourage entrepreneurs from taking such financial advantage of sick people during a national prescription drug shortage. You would hope that no self-respecting pharmaceutical distributor would want to be seen in such a sickening light.
Yet here we are again, trying next week to propose a new law to reinforce what ought to be obvious common morality. Here we are again, spending valuable taxpayer time and money on legislative efforts to reprimand egregiously bad behavior within the U.S. pharmaceutical market.
Our national prescription drug shortage — which sets the dark stage for such successful price-gouging — has been worsening for years in front of our politicians' blind eyes. The number of reported drug shortages each year has more than quadrupled recently — from 61 in 2005, to more than 250 within the current year (so far).
You have to wonder why so little is being done to solve this national health care crisis. Appeals to patient care and safety don't seem to be motivating drugmakers and distributors to do the right thing.
The "new law" to which she refers is one of Chucky Schumer's more idiotic endeavors (Yes, it's that bad). I have a draft blog on that thing, which I'll probably never finish, for what that's worth. (My earlier comments on Schumer's endeavor, here.)
To answer Scannell, the people jacking up prices in the face of the current shortages are doing the moral thing. They are preserving and conserving their supply of drugs. Were they NOT to jack up their prices, their supply would soon be gone like everyone else's, and then there would be no such drugs at any price. I ask Scannell: Which would you prefer, drugs at a market price, however unfair you deem that price to be, or no drugs at all?
Further, whoever acquires said drugs, like the afore mentioned middlemen do, can do anything they want with them, including not selling them at any price. Should Scannell decide to go into the drug distribution business, she might very well choose to sell them below her own cost, but she might also come to realize that doing so is not a sustainable business model, just as it might occur to her (at some point) that hoarding drugs and hoping to sell them at prices no one is willing to pay is also not a sustainable business model.
Scannell's misunderstanding of things goes deeper:
One might reasonably ask: Well, why not just manufacture more drugs to meet the demands of this crisis, and increase the supply to drive down costs? Indeed, aren't drug companies generally happy to make and sell their products?
It isn't the drug manufactuers who are enjoying the difference between low manufacturing cost and high prices. It's middlemen. The drug companies are restricted in several ways (price controls, and quotas, to name two), BY THE GOVERNMENT, from reaping the rewards of doing more business.
Also, it's nonsense to suppose that a company should endeavor to "increase the supply to drive down costs". Scannell is either using the wrong word ("costs") or misunderstanding the driver of economies of scale. In mature products, such as those under consideration, costs are pretty much fixed (though that is another problem Scannell doesn't factor in: Costs for components have been rising), so one suspects that Scannell is conflating "cost" and "price", and still being wrong absent the conflation.
All companies have finite resources. In business terms, it makes no sense for a company to expand production of one line (generic drugs with price contols and quotas) that contributes very little to their bottom line and continued existence, versus promoting those lines that further their continued existence (other drugs that earn the money that sustains the business).
Relatedly, here's another insight from another story I haven't managed to blog: Congress holds hearing on national drug shortage:
Hudspeth and others who plan to testify tomorrow said they believe the shortage is linked to the 2003 Medicare Modernization Act that was supposed to create more transparency in pricing. But it also resulted in the changing of the reimbursement rate for drugs from a percentage of average wholesale price to average selling price, including all discounts. The current model makes it difficult for drug companies to raise prices more than 6 percent a year.
It's good to see someone who has a clue, but I have seen exactly zero reports out of those hearings that were allegedly held at the end of November, though I haven't explicitly searched for them.
What we have, then, is a market that's been thrown out of whack by government interference (ie., the 2003 Medicare Modernization Act and a plethora of other regulations), with middlemen taking advantage of the situation, as middlemen will do, with the government and useful idiots like Scannel now blaming the middlemen for capitalizing on a situation the government created.
I suppose it would be impolite to ask Dr. Scannell if she is a recipient of government funds in her day to day practice.
In any event, it's difficult to tell whether Scannell is just someone who hasn't thought through the things she's written, or whether she's written the things she has in order to perpetuate certain ignorances among the general population.
I would suggest to Dr. Scannell that companies don't often choose not to make money in areas where there is money to be made. If companies are shying away from endeavors that Dr. Scannell thinks obvious money makers, perhaps Dr. Scannell should re-evaluate her assumptions in said regards.
[Edited for typos, readability, and other non-nefarious reasons.]
It's good that more people are understanding the root causes of the country's growing drug shortage problem…
"Essentially all of the drug shortages that occur in the U.S. arise in the generics market, where profitability is fairly low," Greg Conko, of the Competitive Enterprise Institute in Washington, said by email in response to a request for comment from MedPage Today and ABC News.
"Compounding the problem is the fact that the 'buyers' of the drugs in question aren't patients but third-party payers — insurance firms, pharmaceutical benefit managers, and government health programs — all of which have a strong incentive to drive the prices paid for these products down as low as possible.
"So, for many of these drugs, the market can really only sustain a handful of manufacturers — sometimes just one or two. So, when supply disruptions occur — caused by a shortage of raw materials or more often a quality control problem in a manufacturing facility — there aren't a lot of additional producers in the market to take up the slack," Conko said.
Adding to the problem is Medicare's "statutory price inflexibility," which has established a 6% ceiling on price increases in any six-month period. The cap means that manufacturers have little incentive to bring new production online when shortfalls arise.
"What the executive order won't do — can't do — is address the problems with Medicare's pricing rules or the fundamental underlying structure of the marketplace," Conko continued. "But by trying to prevent 'price gouging,' the executive order could actually serve to make drug shortages even worse," Conko said.
Yeah, it's true, and there's more of it, if you care to read it.
But then, when the subject turns to remedies, it's just more of the same bad old government-control bullshit…
Legislative and regulatory control is needed to ensure the predictability of manufacturing and supply, [Bruce A. Chabner, MD, of Massachusetts General Hospital] continued.
One "carrot and stick" scenario would be to require generic manufacturers to submit projections for product demand and production capacity, and to build redundancy into their production capacity to accommodate generics. The requirements would be tied to new drug applications, and companies that performed well would get priority review, whereas companies with a poor track record could have their applications denied.
What is it with people that they just can't let markets work?
The NY Times polishes the turd: "Twenty-five cents of every dollar spent by consumers is regulated by the F.D.A."
Yesterday, the Obama administration likely issued an Executive Order allegedly addressing the growing incidences of drug shortages. See the White House press statement, trumpeting the coming order.
The press release is interesting in a number of ways, most of which I can't take the time to fully address.
While the statement includes several admissions that the bureaucracy is a wrench in the works of excellent and timely drug delivery, there is no call for less bureaucracy. To the contrary, Obama wants the bureaucracy expanded, to better "expedite" the things that the bureaucracy does too slowly now.
One example that illustrates the ignorance (or malfeasance) of the administration is the paragraph titled, "Fighting Price Gouging".
Price controls. Obama might as well decree further shortages.
The section labeled "Key Facts about Drug Shortages" is a list of a few hard facts interspliced with various nebulous criticisms such as, "'Just in time' manufacturing and inventorying practices leave little margin for error." Well, that's true, but why would a company cut things so tightly as to repeatedly fail to meet a customer's order? To Obama and the rest of the socialists, that's a mystery.
What ends up providing some pertinent information in relation to the ongoing drug shortages turns out to come from one of the blowhard bloggers working Ezra Klein's Washington Post spot, who highlight the Presidents Executive Order. Ninety nine percent of the post is worthless, but the "five recommendations" link that leads to the effluvia of the "Drug Shortages Summit Steering Committee", ostensibly representing a "diverse coalition of health-care industries" who emit a rather non-diverse set of legislative and/or regulatory proposals contains a couple of giblets that inform the larger picture.
Actually, one most go to the bottom of the aforementioned link, to the five recommendations (PDF), before one finds the actual five recommendations alluded to in the Klein blog.
What ARE the five recommendations (severely abbreviated except where not, by me) being pushed by the (allegedly diverse) steering committee?
1. Insufficient regulatory resources to manage rapidly escalating drug shortages.
2. Inadequate and incomplete communication of drug shortage information.
3. Lack of contingency plans for critical drugs that are vulnerable to shortages.
4. Inability to quickly respond to shortages of controlled substances.
5. Disincentives to manufacturing older generic injectables.
While all five entries invoke the regulatory environment, the last two surreptitiously describe a couple of the distortions and limitations the government has laid on the pharmaceutical industry.
To whit, on Issue number 4, it is stated…
Regulations for manufacturing and production quotas for controlled substances may limit the ability of the FDA and manufacturers to address drug shortages in an expedited manner. Section 306 of the Controlled Substances Act (CSA) requires that the Attorney General establish aggregate production quotas for schedule II controlled substances. Quotas are set annually in the fall based on factors such as past sales. While manufacturers can request revised quotas at any time, the process is burdensome and can prolong or exacerbate a drug shortage.
Get that? There are government imposed quotas on whole ranges of drugs, curtailing the flexibility of manufacturers in meeting demand for same. The panel doesn't recommend that the quotas be removed, just that the regulatory apparatus respond to quota issues more quickly than it currently does. This is the age old issue that has bedevilled central control authoritarian regimes for decades. One imposes a quota on an industry, then one waits for the quota to be exceeded, then one processes the sundry data, then one attempts to set a new quota, meanwhile the associated manufacturers are in limbo and thinking they might as well hang it up.
No matter how quickly a bureaucracy can emit new quotas, it cannot keep up with the vagaries of the market.
And know that quotas are just one of the government induced problems bedevilling the drug industry.
Price controls are just as pervasive, and just as insidious.
I've GOT to close some tabs. Some of these stories have been sitting there trying to bother me for weeks.
The Perils of Price Controls. Hits the nail on the head (with only a little excessive verbosity), but still as good as any thing else being written on the matter, these days.
—
And here come the commies, all clueless, even as the market begins its end around run. These I've saved because each introduces a different aspect of the increasing shortages, and in each of them, the reporter regurgitates largely the same non-reason reasons for the shortages, and never come close to the real meat.
Health News: Drug shortages continue to climb; price-gouging breaks out; feds meet with drugmakers
Cancer Drug Shortages Delay, Stop Work On Clinical Trials
Hospital Drug Shortages Present Costly Crisis
That last one rolls all the hysteria up into one clueless ball, never even dreaming about putting the finger where it belongs.
(Remembered I had this one mostly written in the hopper.)
Forbes coughs out a look at the increasing drug shortages…
Doctors have resorted to rationing, forcing patients to either go without or use inferior substitutes. Clinical trials are being interrupted, wreaking havoc on the approval of new and more effective drugs. Shady black markets have emerged to fill the gap – a worrying trend given the importance of purity and proper handling.
I've got stories marked on all those aspects, though the black market side of things isn't what I would call worrying, yet. So far, it's a little like ticket scalping, meaning you'll pay more, but you'll still get in to the concert. Perhaps fascinatingly, it's doctors and hospital administrators going outside the usual channels, trying to serve their customers.
And then the sundry excuses are offered up by a HHS flack, all nebulous, leading to the inevitable knockdown:
Funny, but those sorts of challenges occur every day in a wide variety of industries without causing chronic shortages.
A wide variety of industries don't have the government breathing down their necks like health care corps do every day of the year.
Forbes' economic analysis and rebuttal is essentially correct, though a little short on specifics:
Fix prices by government fiat by specifying a certain level of Medicare reimbursement (which also sets a benchmark for private insurers), and the reverse information flow is destroyed. Remove the ability to raise prices when demand exceeds supply and shortages will follow as sure as night follows day. Policies that keep prices too low for too long incentivize suppliers to exit the business. Consolidation follows, making the supply chain more prone to disruptions. And disruptions become more likely, as prices can’t rise to encourage survivors to invest in updating and maintaining their manufacturing systems.
It's the ol' government squeeze, and politicians and the general commie hordes have been railing against pharmaceutical profits for YEARS. Well, shortages and consolidation (business closure) are what you get when you finally squeeze the profit out of an industry.
Somebody call fucking Chuck Schumer.
It's tough being stoopit, I guess:
Two years into an escalating shortage of life-saving cancer drugs, regulators and lawmakers are still unable to identify why it is happening, let alone how to solve the problem.
Fucking Chuck Schumer has called for an investigation, as though he couldn't look in the mirror and see one of the culprits.
The video at the bottom is another fucking disgrace. Bobble heads for government involvement.
Here's another story, with more buffoons:
Aiello’s doctor, Eyal Attar, uses much stronger language. “It’s absolutely outrageous that we cannot have these drugs available in our country – with one of the most advanced medical systems available to treat our patients. It is very frustrating and it makes me, quite frankly, angry.”
Fuck you, you moron.
And the usual…
There is no single reason for the shortages. Some pharmaceutical companies have experienced manufacturing delays. Raw materials may be in short supply. And because most of these drugs have been off-patent for years, some drug companies don’t want to spend the money to upgrade lines to produce drugs with slim profit margins.
But there is a single reason for the shortages. It's called profit, the second to last word in the paragraph just above. Life saving drugs, you know, drugs that people need to save their own lives, have slim profit margins, and apparently, people would rather die than pay more? Is that it?
I don't think so. It's just that someone or some thing is not allowed to pay more. Maybe. And who would be doing that forbidding? Anyone? Bueller?
But wait, there's more…
There is money to be made, though. The shortage has given rise to a burgeoning “gray” market for hospital drugs.
“For some reason they have the supplies,” says Emory’s Emamifar, “but they’re selling at exorbitant prices.
FOR SOME REASON? FOR SOME FUCKING REASON?
How does Emamifar manage to run a pharmacy at a major hospital and not know the reason?
And notice THAT. It's not that people aren't allowed to pay more for their life saving drugs. It's that the official suppliers are not allowed to CHARGE more. When things are piped through the gray market, the increased price is paid, and gladly.
Oops, had another shortage story open (though now I think about it, I've got another half dozen drug shortage windows open… damn):
Similar to 2010, the drugs most affected by this year's shortages are older, sterile injectables, which are mostly used in hospitals. Part of the problem is that too few manufacturers produce the medications to meet the nation's needs, the FDA said.
Many companies choose not to make these products because they are not as profitable as other drugs, and manufacturing them is complex, medical experts say.
Yep, again. People are dying for these drugs, but they are not sufficiently profitable to manufacture and deliver. But the gray market means that patients and doctors are willing and able to pay more for these drugs, so that can only mean that the drug makers themselves are not allowed to charge a price that will please the market.
As I previously pointed out, quoting the inept and shoddy New York Times:
[C]ancer patients do not buy chemotherapy drugs from their local pharmacies the way they buy asthma inhalers or insulin. Instead, it is their oncologists who buy the drugs, administer them and then bill Medicare and insurance companies for the costs.
Historically, this “buy and bill” system was quite lucrative; drug companies charged Medicare and insurance companies inflated, essentially made-up “average wholesale prices.” The Medicare Prescription Drug, Improvement and Modernization Act of 2003, signed by President George W. Bush, put an end to this arrangement. It required Medicare to pay the physicians who prescribed the drugs based on a drug’s actual average selling price, plus 6 percent for handling. And indirectly — because of the time it takes drug companies to compile actual sales data and the government to revise the average selling price — it restricted the price from increasing by more than 6 percent every six months.
The act had an unintended consequence. In the first two or three years after a cancer drug goes generic, its price can drop by as much as 90 percent as manufacturers compete for market share. But if a shortage develops, the drug’s price should be able to increase again to attract more manufacturers. Because the 2003 act effectively limits drug price increases, it prevents this from happening. The low profit margins mean that manufacturers face a hard choice: lose money producing a lifesaving drug or switch limited production capacity to a more lucrative drug.
Price controls on the manufacturers.
Someone call fucking Chuck Schumer.
Counting the costs in Massachusetts…
The study found that health care reform has slowed the amount of investment in state businesses by as much as $29 million, causing Massachusetts to employ between 15,000 and 21,000 fewer people. That’s meant an average of $376 less in disposable income for state residents, according to the report.
“The health care law does not exist in a vacuum,” said David Tuerck, the executive director of the Beacon Hill Institute. “The ‘shared sacrifice’ needed to provide universal health care includes a net loss of jobs, which is attributable to the higher costs that the measure imposed.”
Who could have guessed?
I suspect that that little crimp of 15,000 to 21,000 jobs includes the 18,000 health care related jobs added in Massachusetts above what otherwise might have been without the advent of RomneyCare…
Since Massachusetts enacted the Health Care Reform Plan in early 2006, total health care employment per capita in the state has grown more rapidly than that in the rest of the country. From January 2001 to December 2005, employment per capita grew by just over 8% in both Massachusetts and rest of the country. Subsequently, health care employment grew faster in Massachusetts, increasing by 9.5% from December 2005 through September 2010, while the rate of growth in the rest of the country was 5.5%. Most of the divergence in employment growth between Massachusetts and the rest of the country occurred in 2006 and 2007, when the Massachusetts reforms were being phased in. Had health care employment in Massachusetts grown at the same rate as in the rest of the country, approximately 18,000 fewer people would have been employed in health care by 2010.
Most of the difference in health care employment growth occurred in administrative occupations.
Administrative positions don't reek of productivity.
But, you know, there have been BIG changes in Massachusetts, health care wise. Instead of spending $700 million a year treating the uninsured, the state now spends "about $1.8 billion" to treat the pseudo-insured and the still sizable number of the uninsured lingering at the edges.
I think the free lunch is eating Massachusetts.
I yield a few lines to the fucked-in-the-head Republican Senator from the Great State of Maine…
The causes of drug shortages vary but generally fall into four main categories: 1) shortages of raw materials or manufacturing difficulties, such as contamination problems or equipment failures; 2) reduced factory capacity due to industry consolidations; 3) companies dropping older, less profitable drugs, leaving manufacturing in the hands of fewer companies; and 4) regulatory and legislative factors such as the absence of FDA authority to require manufacturers to provide notice of an anticipated withdrawal of a drug from the market.
What a stupid twit.
One of those four things Collins listed is not like the others in that the first three have to do with markets, such as they are in the modern, heavily regulated pharmaceutical sector, and the fourth, doesn't. The fourth also has no bearing on the growing scarcity of prescription drugs, at least not until the new law that Collins has co-sponsored is set loose upon the land, whereupon it will become another burden on over-burdened businesses, further exacerbating the shortages.
As to items 1), 2), and 3), they are all red herrings. Certainly such things can lead to temporary disruptions in a market, but such things are the things that competitors capitalize on and that innovators are spurred to innovation on, erasing such disruptions. The reason there exists, not temporary and rare disruptions, but continuing and growing shortages is because the drug makers' biggest customer has inflicted price controls on prescription drugs as an attack on what are termed unseemly profits, and by otherwise inhibiting the usual mechanisms by which markets adapt to disruptions.
And it's plain that moron Susan Collins has neither the understanding of the issue, nor the inclination to do other than to make it worse.
"Free" health care blowing a gasket in Ontario finances.
Hsieh: The Coming Collectivization of American Health Care
Drug shortages. The problem has been growing since the early days of the Clinton years, when Hillary devoted herself to insuring that the supply of childhood vaccines would henceforth be subject to political whims, and I've followed the issue all that time, usually marveling at the incompetence of the professional media in reporting the story. But today's New York Times lays it out about as plainly as I've seen.
With one or two ridiculous asides, of course…
If the laws of supply and demand were working properly, a drug shortage would cause a price rise that would induce other manufacturers to fill the gap. But such laws do not really apply to cancer drugs.
The laws of supply and demand always apply. That's why they're referred to as laws.
The Times goes on to refute its own ignorant propaganda against free markets. They start with a little tap dance of frivolities…
The underlying reason for this is that cancer patients do not buy chemotherapy drugs from their local pharmacies the way they buy asthma inhalers or insulin. Instead, it is their oncologists who buy the drugs, administer them and then bill Medicare and insurance companies for the costs.
Historically, this “buy and bill” system was quite lucrative; drug companies charged Medicare and insurance companies inflated, essentially made-up “average wholesale prices.”
Current shortages have nothing to do with the miscellany of how the drugs are paid for, or whether someone made money along the way. This particular story isn't one of patients being insulated from the true cost of the products they utilize (though there may be a little bit of that, too), but rather more glaringly an artificially introduced bottleneck further down the line…
The Medicare Prescription Drug, Improvement and Modernization Act of 2003, signed by President George W. Bush, put an end to this arrangement.
No shit.
It required Medicare to pay the physicians who prescribed the drugs based on a drug’s actual average selling price, plus 6 percent for handling. And indirectly — because of the time it takes drug companies to compile actual sales data and the government to revise the average selling price — it restricted the price from increasing by more than 6 percent every six months.
The act had an unintended consequence. In the first two or three years after a cancer drug goes generic, its price can drop by as much as 90 percent as manufacturers compete for market share. But if a shortage develops, the drug’s price should be able to increase again to attract more manufacturers. Because the 2003 act effectively limits drug price increases, it prevents this from happening. The low profit margins mean that manufacturers face a hard choice: lose money producing a lifesaving drug or switch limited production capacity to a more lucrative drug.
The result is clear: in 2004 there were 58 new drug shortages, but by 2010 the number had steadily increased to 211. (These numbers include noncancer drugs as well.)
There it is.
The current drug shortages are not the result of a failure in the laws of supply and demand, but are the undeniable consequence of government meddling.
To further round things out in the blame fixing department, note that the aforementioned Act was introduced and relentlessly flogged by Republican Denny Hastert, and subsequently passed with great difficulty by the dear Republicans of the day, and duly signed by the bumpkin George Dubya Bush.
Fuck every last one of them.
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 | ||||||